WO2024254218A3 - Modulateurs d'interaction protéine-protéine complexe de canal fgf14:nav1.6 à petites molécules non peptidiques - Google Patents

Modulateurs d'interaction protéine-protéine complexe de canal fgf14:nav1.6 à petites molécules non peptidiques Download PDF

Info

Publication number
WO2024254218A3
WO2024254218A3 PCT/US2024/032668 US2024032668W WO2024254218A3 WO 2024254218 A3 WO2024254218 A3 WO 2024254218A3 US 2024032668 W US2024032668 W US 2024032668W WO 2024254218 A3 WO2024254218 A3 WO 2024254218A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
fgf14
small molecule
channel complex
peptide small
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/032668
Other languages
English (en)
Other versions
WO2024254218A2 (fr
Inventor
Jia Zhou
Fernanda LAEZZA
Pingyuan WANG
Nolan M. DVORAK
Paul A. WADSWORTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2024254218A2 publication Critical patent/WO2024254218A2/fr
Publication of WO2024254218A3 publication Critical patent/WO2024254218A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux modulateurs d'interaction protéine-protéine complexe de canal FGF14:NAV1.6 à petites molécules de la structure générale selon la formule (I), et ainsi que leur préparation et leur utilisation.
PCT/US2024/032668 2023-06-05 2024-06-05 Modulateurs d'interaction protéine-protéine complexe de canal fgf14:nav1.6 à petites molécules non peptidiques Pending WO2024254218A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506356P 2023-06-05 2023-06-05
US63/506,356 2023-06-05

Publications (2)

Publication Number Publication Date
WO2024254218A2 WO2024254218A2 (fr) 2024-12-12
WO2024254218A3 true WO2024254218A3 (fr) 2025-04-17

Family

ID=93794700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/032668 Pending WO2024254218A2 (fr) 2023-06-05 2024-06-05 Modulateurs d'interaction protéine-protéine complexe de canal fgf14:nav1.6 à petites molécules non peptidiques

Country Status (1)

Country Link
WO (1) WO2024254218A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920127A (en) * 1987-02-18 1990-04-24 Beecham Group P.L.C. Substituted indoles and their use as 5-HT3 receptor antagonists
US5444152A (en) * 1990-06-07 1995-08-22 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic peptide derivatives
WO2004099189A1 (fr) * 2003-05-09 2004-11-18 F. Hoffmann-La Roche Ag Methyle indoles et methyle pyrrolopyridines servant d'agonistes du recepteur adrenergique alpha-1
US20150148349A1 (en) * 2012-06-28 2015-05-28 Novartis Ag Complement pathway modulators and uses thereof
US20190055196A1 (en) * 2015-06-09 2019-02-21 Abbvie Inc. Nuclear receptor modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920127A (en) * 1987-02-18 1990-04-24 Beecham Group P.L.C. Substituted indoles and their use as 5-HT3 receptor antagonists
US5444152A (en) * 1990-06-07 1995-08-22 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic peptide derivatives
WO2004099189A1 (fr) * 2003-05-09 2004-11-18 F. Hoffmann-La Roche Ag Methyle indoles et methyle pyrrolopyridines servant d'agonistes du recepteur adrenergique alpha-1
US20150148349A1 (en) * 2012-06-28 2015-05-28 Novartis Ag Complement pathway modulators and uses thereof
US20190055196A1 (en) * 2015-06-09 2019-02-21 Abbvie Inc. Nuclear receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Compound 12 April 2007 (2007-04-12), PUBCHEM: "3-Methylindole-1-carboxamide | C10H10N2O | CID 17913525 - PubChem", XP093305536, Database accession no. 17913525 *

Also Published As

Publication number Publication date
WO2024254218A2 (fr) 2024-12-12

Similar Documents

Publication Publication Date Title
Tam et al. Membranolytic selectivity of cystine‐stabilized cyclic protegrins
WO2023288241A8 (fr) Anticorps anti-récepteur de chimiokine à motif c-c 8 (ccr8) et méthodes d'utilisation
RU95116650A (ru) Гидрат кальпотриола и фармацевтическая композиция
CA2421880A1 (fr) Derives de resorcinol
WO2003020756A3 (fr) Expression hybride et en tandem de proteines de neisseria
WO2004099231A3 (fr) Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
HUP0402458A2 (hu) Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek
BR0207583A (pt) Derivados de poliamida possuindo atividade antibacteriana, antifungo ou antitumor
TR200102338T2 (tr) Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar.
WO2024108155A3 (fr) Composés, compositions et méthodes
WO2022067214A3 (fr) Polypeptides variants de mu-diguétoxine dc1a pour la lutte antiparasitaire
MX2023009045A (es) Derivados novedosos de pirimidin-2-il sulfonamida.
WO2024254218A3 (fr) Modulateurs d'interaction protéine-protéine complexe de canal fgf14:nav1.6 à petites molécules non peptidiques
EP0805685A4 (fr) Nouveaux cyclohexapeptides antifongiques
WO2006060424A3 (fr) Inhibiteurs de la dimerisation de l'oxyde nitrique synthase inductible
MX2021008632A (es) Moléculas cíclicas como inhibidores de la tirosina cinasa de bruton.
WO2025024329A3 (fr) Composés, compositions et procédés
MX2023005197A (es) Dominio de union a antigeno con tasa de recorte reducida.
WO2022081728A3 (fr) Polypeptides d'interleukine 2 (il-2) modifiés, et leurs procédés de fabrication et d'utilisation
Kapoerchan et al. ‘Inverted’analogs of the antibiotic gramicidin S with an improved biological profile
WO2023147511A3 (fr) Systèmes d'amplification de protéines rep et cap d'aav
CN102596218A (zh) 新型杆菌肽抗生素
WO2024126795A8 (fr) Cellules déficientes en apobec pour la production de vecteurs adénoviraux
WO2001064715A3 (fr) Peptides memno et procede de preparation et d"utilisation associe
Tamaki et al. Fatty acyl-gramicidin S derivatives with both high antibiotic activity and low hemolytic activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2024819976

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024819976

Country of ref document: EP

Effective date: 20260105

ENP Entry into the national phase

Ref document number: 2024819976

Country of ref document: EP

Effective date: 20260105

ENP Entry into the national phase

Ref document number: 2024819976

Country of ref document: EP

Effective date: 20260105

ENP Entry into the national phase

Ref document number: 2024819976

Country of ref document: EP

Effective date: 20260105

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24819976

Country of ref document: EP

Kind code of ref document: A2